Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
101. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
13-02-2017 |
View |
102. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |
103. |
ECCT/16/09/03 | Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya. |
Principal Investigator(s) 1. Dr.Pauline NM Mwinzi Site(s) in Kenya KEMRI CGHR |
28-11-2016 |
View |
104. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
27-10-2016 |
View |
105. |
ECCT/16/07/05 | HESTIA 1 Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county) 3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county) 4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county) |
19-09-2016 |
View |
106. |
ECCT/16/05/01 | A5338 A5338 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) |
Principal Investigator(s) 1. David Schnabel Site(s) in Kenya KISUMU CRS |
28-07-2016 |
View |
107. |
ECCT/16/06/01 | P1115 Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya KEMRI WALTER REED PROJECT KERICHO |
25-07-2016 |
View |
108. |
ECCT/16/04/01 | HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection HVTN 703/HPTN 081 A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection |
Principal Investigator(s) 1. Dr. Victor Akelo Akelo Site(s) in Kenya KISUMU CRS |
14-07-2016 |
View |
109. |
ECCT/16/03/02 | Infant TB Infection Prevention Study (“iTIPSâ€) Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants |
Principal Investigator(s) 1. Grace John-Stewart Site(s) in Kenya 1. Kisumu East District Hospital (Kisumu county) 2. Ahero County Hospital (Kisumu county) 3. Bondo sub-County Hospital (Kisumu county) |
03-06-2016 |
View |
110. |
ECCT/16/02/05 | PfSPZ Malaria Vaccine Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months through 12 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age de-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy |
Principal Investigator(s) 1. Martina Oneko 2. Mary J Hamel Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Wagai Health Center (Siaya county) |
18-05-2016 |
View |